Condition
X-Linked Chronic Granulomatous Disease
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Terminated2
Recruiting2
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06876363Phase 1RecruitingPrimary
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT01855685Phase 1TerminatedPrimary
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
NCT02757911Phase 1TerminatedPrimary
Gene Therapy for X-linked Chronic Granulomatous Disease
NCT06325709Phase 1Recruiting
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
NCT01906541Phase 1UnknownPrimary
Gene Therapy for X-CGD
Showing all 5 trials